Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the keytruda market grown over the years?

There has been a swift expansion in the size of the keytruda market in the past few years. It is projected to rise from a value of $21.6 billion in 2024 to $23.8 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.2%. The growth experienced in the past can be credited to improved results for patients, a greater use of immunotherapy, advances in research and development, better adherence by patients, and a higher rate of keytruda adoption.

What Is the forecasted market size and growth rate for the keytruda market?

Anticipations of significant expansion are in place for the keytruda market over the impending years, with predictions of reaching a value of $34.61 billion by 2029, marking a compound annual growth rate (CAGR) of 9.8%. The predicted growth for this period could be a reflection of several factors such as increased indications, the rise of budding markets, the escalating incidences of cancer, an upsurge in healthcare expenditure, and an increased call for precision medicine. Noteworthy trends forecasted for this period encompass the need for targeted therapies, progressions in immunotherapy and diagnostic technologies, a growing demand for cancer treatments, and advancements in cancer research.

Get your keytruda market report here!

https://www.thebusinessresearchcompany.com/report/keytruda-global-market-report

What are the major factors driving growth in the keytruda market?

The surge in cancer cases is anticipated to fuel the expansion of the keytruda market moving forward. Cancer, a multifaceted set of diseases, is distinguished by irregular cellular growth and propagation. Genetic, lifestyle, environmental, and hormonal aspects contribute to its occurrence. Keytruda (pembrolizumab) aids in fighting cancer by optimizing the body’s immunity system to combat cancerous cells more effectively. It denotes a significant progression in cancer treatment by leveraging the power of the immune system to target and eradicate cancer cells, offering renewed optimism for numerous patients with advanced or metastasized cancers. For example, The American Cancer Society reported in January 2024 that the number of cancer diagnoses increased to 2,001,140 from 1,958,310 in 2023, indicating a growth rate of 2.19%. Hence, the escalating prevalence of cancer propels the keytruda market.

What key areas define the segmentation of the global keytruda Market?

The keytruda market covered in this report is segmented –

1) By Cancer Type: Melanoma, Lung Cancer, Head And Neck Cancer, Hodgkin Lymphoma, Stomach Cancer, Urothelial Carcinoma

2) By Payer Type: Commercial, Medicare, Medicaid

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Melanoma: Advanced Or Unresectable Melanoma, Adjuvant Treatment For Melanoma

2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Recurrent Or Metastatic Head And Neck Cancer

4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma

5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer, Esophagogastric Junction Cancer

6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Cancer

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16457&type=smp

What are the top market players propelling the growth of the keytruda industry?

Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

How are evolving market trends shaping keytruda Strategies?

Significant players in the Keytruda market are spearheading the development of novel products like pembrolizumab to broaden the scope of available treatments. Pembrolizumab is a type of monoclonal antibody medication, classified as an immune checkpoint inhibitor, and is marketed under the Keytruda brand name. The drug operates by targeting and obstructing a protein known as PD-1 (programmed cell death protein 1) located on T immune cells. To illustrate, Merck, a US-based Keytruda manufacturer, debuted KEYTRUDA (pembrolizumab) in conjunction with fluoropyrimidine and platinum-enriched chemotherapy, accredited by the US Food and Drug Administration in November 2023. The paired therapy has been noted for marked boosts in total and progression-free survival rates compared to solo chemotherapy, marking it as a positive breakthrough in gastric cancer treatment. Clinical trials of this duo therapy has shown increases in total survival (OS), progression-free survival (PFS), and the overall response rate (ORR) in comparison to chemotherapy as a standalone therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16457

What regions are dominating the keytruda market growth?

North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Automotive Smart Key Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/automotive-smart-key-global-market-report

Whiskey Warehousing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/whiskey-warehousing-global-market-report

Public Key Infrastructure Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/public-key-infrastructure-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: